Bristol Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL, and what generic alternatives to BRISTOL drugs are available?
BRISTOL has one hundred and sixteen approved drugs.
There are fifty-five US patents protecting BRISTOL drugs.
There are one thousand six hundred and ninety patent family members on BRISTOL drugs in fifty-eight countries and three hundred and nine supplementary protection certificates in nineteen countries.
Summary for Bristol
International Patents: | 1690 |
US Patents: | 55 |
Tradenames: | 93 |
Ingredients: | 81 |
NDAs: | 116 |
Drug Master File Entries: | 1 |
Patent Litigation for Bristol: | See patent lawsuits for Bristol |
PTAB Cases with Bristol as patent owner: | See PTAB cases with Bristol as patent owner |
Drugs and US Patents for Bristol
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | AMITID | amitriptyline hydrochloride | TABLET;ORAL | 086454-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol Myers Squibb | ESTRACE | estradiol | TABLET;ORAL | 084499-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-002 | Jun 28, 2006 | RX | Yes | No | 8,680,103*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bristol
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 6,869,399 | ⤷ Try a Trial |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 8,204,763 | ⤷ Try a Trial |
Bristol Myers Squibb | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 5,635,517 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
➤ Subscribe | Capsules | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2017-02-08 |
➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
International Patents for Bristol Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Montenegro | P58108 | ⤷ Try a Trial |
Eurasian Patent Organization | 201270738 | ⤷ Try a Trial |
South Korea | 20090028821 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2922846 | 122023000049 | Germany | ⤷ Try a Trial | PRODUCT NAME: DEUCRAVACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1718 20230324 |
0582455 | 2008/016 | Ireland | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF EFAVIRENZ AND EMTRICTABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/07/430/001 20071213 |
2049522 | 92635 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES , EN PARTICULIER DICHLORHYDRATE DE DACLATASVIR. FIRST REGISTRATION: 20140826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.